MARKET

APLS

APLS

Apellis Pharmace
NASDAQ
58.78
+0.29
+0.50%
After Hours: 58.75 -0.03 -0.05% 19:59 03/28 EDT
OPEN
58.47
PREV CLOSE
58.49
HIGH
58.96
LOW
56.82
VOLUME
1.25M
TURNOVER
0
52 WEEK HIGH
94.75
52 WEEK LOW
19.83
MARKET CAP
7.09B
P/E (TTM)
-13.1962
1D
5D
1M
3M
1Y
5Y
PLAB, SMTC and WOOF are among after hour movers
On the Move PLAB, SMTC and WOOF are among after hour movers. Semtech Corporation, ANAB and ZNTL are among the biggest gainers in the biotech sector. PLAB and SMTC were among the largest losers in the pharmaceutical sector.
Seeking Alpha · 10h ago
CCL, SPB, RARE, and VRSK are new additions to GS’ Long Duration Basket
GS’ Long Duration basket returned 3% year-to-date, compared to 6% for the equal-weight S&P 500 (RSP) Goldman Sachs analysts expect inflation to continue to be low and real yields to remain close to current levels. CCL, SPB, RARE, and VRSK are new additions to GS' Long Duration Basket.
Seeking Alpha · 13h ago
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS): Is Breakeven Near?
Apellis Pharmaceuticals, Inc. Is a commercial-stage biopharmaceutical company. The company posted a loss of US$529m for its most recent financial year. Analysts expect the company to post a final loss in 2024, before turning a profit in 2025. Apellis pharmaceuticals currently has a high level of debt. It is predicted to be profitable in 2023.
Simply Wall St · 16h ago
Decoding 15 Analyst Evaluations For Apellis Pharmaceuticals
Apellis Pharmaceuticals has been analyzed by 15 analysts in the last three months. The company has an average 12-month price target of $79.4 and a high estimate of $106.00. Apellis pharmaceuticals is a biopharmaceutical company focused on the inhibition of the complement system.
Benzinga · 1d ago
Apellis Pharmaceuticals Is Maintained at Neutral by Mizuho
Dow Jones · 1d ago
Mizuho Maintains Neutral on Apellis Pharmaceuticals, Maintains $60 Price Target
Benzinga · 1d ago
Weekly Report: what happened at APLS last week (0318-0322)?
Weekly Report · 3d ago
Analysts Offer Insights on Healthcare Companies: eFFECTOR Therapeutics (EFTR), Apellis Pharmaceuticals (APLS) and Ultragenyx Pharmaceutical (RARE)
TipRanks · 03/19 11:10
More
About APLS
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan), is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and United Kingdom.

Webull offers Apellis Pharmaceuticals Inc stock information, including NASDAQ: APLS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APLS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading APLS stock methods without spending real money on the virtual paper trading platform.